NASDAQ:ANIX

Anixa Biosciences (ANIX) Stock Forecast, Price & News

$3.26

-0.08 (-2.40%)

(As of 09/26/2023 ET)

Compare

Today's Range: $3.25
▼
$3.40
50-Day Range: $3.26
▼
$3.86
52-Week Range: $2.90
▼
$6.45

Volume: 15,071 shs
Average Volume: 46,708 shs
Market Capitalization: $101.29 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.50

Anixa Biosciences MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 222.1% Upside
$10.50 Price Target
Short Interest: Healthy
2.12% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.18
Based on 6 Articles This Week
Insider Trading: Selling Shares
$42,126 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.32) to ($0.37) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.31 out of 5 stars

Medical Sector

310th out of 964 stocks

Pharmaceutical Preparations Industry

124th out of 438 stocks

3.5

Analyst's Opinion

Consensus Rating
Anixa Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $10.50, Anixa Biosciences has a forecasted upside of 222.1% from its current price of $3.26.
Amount of Analyst Coverage
Anixa Biosciences has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
2.12% of the float of Anixa Biosciences has been sold short.
Short Interest Ratio / Days to Cover
Anixa Biosciences has a short interest ratio ("days to cover") of 8.1.
Change versus previous month
Short interest in Anixa Biosciences has recently decreased by 4.00%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Anixa Biosciences does not currently pay a dividend.
Dividend Growth
Anixa Biosciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ANIX.

4.0

News and Social Media Coverage

News Sentiment
Anixa Biosciences has a news sentiment score of 1.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Anixa Biosciences this week, compared to 1 article on an average week.
Search Interest
4 people have searched for ANIX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
MarketBeat Follows
2 people have added Anixa Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Anixa Biosciences insiders have sold 110.42% more of their company's stock than they have bought. Specifically, they have bought $20,020.00 in company stock and sold $42,126.00 in company stock.
Percentage Held by Insiders
20.40% of the stock of Anixa Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 11.78% of the stock of Anixa Biosciences is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Anixa Biosciences are expected to decrease in the coming year, from ($0.32) to ($0.37) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Anixa Biosciences is -9.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Anixa Biosciences is -9.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Anixa Biosciences has a P/B Ratio of 3.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Anixa Biosciences (NASDAQ:ANIX) Stock

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

ANIX Price History

30 days | 90 days | 365 days | Advanced Chart

ANIX Stock News Headlines

September 22, 2023 | americanbankingnews.com

Anixa Biosciences, Inc. Forecasted to Post FY2023 Earnings of ($0.32) Per Share (NASDAQ:ANIX)

September 21, 2023 | finance.yahoo.com

ANIXA BIOSCIENCES INC (ANIX) Upgraded to Buy: What Does It Mean for the Stock?

September 27, 2023 | Wall Street Fundamentals (Ad)

The "Plug and Play" Model Putting Online Giants to Shame

While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."

September 19, 2023 | finance.yahoo.com

Anixa Biosciences Establishes Cancer Business Advisory Board

September 19, 2023 | americanbankingnews.com

Anixa Biosciences (NASDAQ:ANIX) Receives "Buy" Rating from HC Wainwright

September 19, 2023 | finance.yahoo.com

The 3 Most Undervalued Cheap Stocks to Buy in September 2023

September 18, 2023 | markets.businessinsider.com

Anixa Biosciences (ANIX) Receives a Buy from H.C. Wainwright

September 10, 2023 | finance.yahoo.com

Here's Why We're Not Too Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Situation

September 27, 2023 | Wall Street Fundamentals (Ad)

The "Plug and Play" Model Putting Online Giants to Shame

August 31, 2023 | msn.com

Anixa Biosciences (ANIX) Price Target Increased by 14.29% to 12.24

August 31, 2023 | finance.yahoo.com

Anixa Biosciences to Participate in September Investor Conferences

August 28, 2023 | finance.yahoo.com

Anixa Biosciences Announces Treatment of Third Patient in Ovarian Cancer CAR-T Clinical Trial

August 25, 2023 | msn.com

Anixa Biosciences: Early Stage, Low Cash. Does It Matter?

August 16, 2023 | msn.com

Small Biotech Company Hopes its Vaccine Will End Breast Cancer

August 15, 2023 | msn.com

Biotech Company Hopes to Eliminate Breast Cancer with a Vaccine

August 14, 2023 | finance.yahoo.com

Anixa Biosciences Announces Invited Presentation on Ovarian Cancer CAR-T Therapy at the 8th Annual CAR-TCR Summit

August 10, 2023 | finanznachrichten.de

Anixa Biosciences, Inc.: Could Anixa Biosciences Be Developing The Vaccine To End One Of The Deadliest Types Of Breast Cancer?

August 10, 2023 | finance.yahoo.com

Could Anixa Biosciences (NASDAQ:ANIX) Be Developing The Vaccine To End One Of The Deadliest Types Of Breast Cancer?

August 9, 2023 | benzinga.com

Could Anixa Biosciences (NASDAQ: ANIX) Be Developing The Vaccine To End One Of The Deadliest Types Of Breast Cancer?

July 28, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Anixa Biosciences (ANIX), Roche Holding AG (OtherRHHVF) and Bristol-Myers Squibb (BMY)

July 27, 2023 | finance.yahoo.com

Anixa Biosciences Announces Notice of Allowance of Additional Patent on Ovarian Cancer Vaccine Technology

July 25, 2023 | msn.com

Ohio woman part of groundbreaking breast cancer vaccine trial

July 24, 2023 | msn.com

NE Ohio woman part of groundbreaking breast cancer vaccine trial

July 24, 2023 | finance.yahoo.com

Gilead (GILD) Ends Myelodysplastic Syndromes Study on Magrolimab

July 24, 2023 | benzinga.com

Anixa Biosciences And 2 Other Penny Stocks Insiders Are Aggressively Buying

July 21, 2023 | finance.yahoo.com

Vir Biotechnology (VIR) Down on Influenza Study Failure

July 12, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Its Buy Rating for Anixa Biosciences (ANIX)

See More Headlines

Receive ANIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anixa Biosciences and its competitors with MarketBeat's FREE daily newsletter.

ANIX Company Calendar

Last Earnings: 8/31/2021
Today: 9/27/2023
Fiscal Year End: 10/31/2023
Next Earnings (Estimated): 1/03/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ANIX
CUSIP: N/A
CIK: 715446
Web: www.anixa.com
Phone: (408) 708-9808
Fax: 631-549-5974
Employees: 4
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $10.50
High Stock Price Forecast: $12.00
Low Stock Price Forecast: $9.00
Forecasted Upside/Downside: +222.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.35)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-13,600,000.00
Net Margins: N/A
Pretax Margin: -5,113.33%
Return on Equity: -40.14%
Return on Assets: -37.55%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 14.22
Quick Ratio: 14.22

Sales & Book Value

Annual Sales: $510,000.00
Price / Sales: 198.60
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.92 per share
Price / Book: 3.54

Miscellaneous

Outstanding Shares: 31,070,000
Free Float: 24,732,000
Market Cap: $101.29 million
Optionable: Not Optionable
Beta: 0.94

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. Amit Kumar Ph.D. (Age 59)
Chairman & CEO
Comp: $1.07M

Mr. Michael J. Catelani CPA (Age 56)
MBA, Pres, COO, CFO & Corp. Sec.
Comp: $550.96k

Mr. John Roop (Age 73)
Sr. VP of Engineering

Dr. Thomas Schlumpberger Ph.D. (Age 57)
Exec. VP of Diagnostics

Dr. Pamela D. Garzone Ph.D. (Age 68)
Chief Devel. Officer & Chair Breast Cancer Clinical Advisory Board

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ANIX Stock - Frequently Asked Questions

Should I buy or sell Anixa Biosciences stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Anixa Biosciences in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ANIX shares.
View ANIX analyst ratings or view top-rated stocks.
What is Anixa Biosciences' stock price forecast for 2023?: 2 Wall Street analysts have issued 1 year target prices for Anixa Biosciences' shares. Their ANIX share price forecasts range from $9.00 to $12.00. On average, they expect the company's stock price to reach $10.50 in the next year. This suggests a possible upside of 222.1% from the stock's current price.
View analysts price targets for ANIX or view top-rated stocks among Wall Street analysts.
How have ANIX shares performed in 2023?: Anixa Biosciences' stock was trading at $4.25 at the beginning of the year. Since then, ANIX shares have decreased by 23.3% and is now trading at $3.26.
View the best growth stocks for 2023 here.
When is Anixa Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, January 3rd 2024.
View our ANIX earnings forecast.
How were Anixa Biosciences' earnings last quarter?: Anixa Biosciences, Inc. (NASDAQ:ANIX) released its quarterly earnings results on Tuesday, August, 31st. The company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by $0.06.
What other stocks do shareholders of Anixa Biosciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Anixa Biosciences investors own include Cronos Group (CRON), Innovative Industrial Properties (IIPR), Roku (ROKU), Ally Financial (ALLY), Albireo Pharma (ALBO), Air Lease (AL), Akoustis Technologies (AKTS), Akero Therapeutics (AKRO), Aimmune Therapeutics (AIMT) and Advanced Emissions Solutions (ADES).

What is Anixa Biosciences' stock symbol?: Anixa Biosciences trades on the NASDAQ under the ticker symbol "ANIX."
Who are Anixa Biosciences' major shareholders?: Anixa Biosciences' stock is owned by many different institutional and retail investors. Top institutional investors include Geode Capital Management LLC (0.98%), BlackRock Inc. (0.81%), Renaissance Technologies LLC (0.19%), Northern Trust Corp (0.17%), JPMorgan Chase & Co. (0.09%) and Tyler Stone Wealth Management (0.07%). Insiders that own company stock include Amit Kumar, Arnold M Baskies, Emily Gottschalk, Lewis H Titterton Jr and Michael Catelani.
View institutional ownership trends.
How do I buy shares of Anixa Biosciences?: Shares of ANIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Anixa Biosciences' stock price today?: One share of ANIX stock can currently be purchased for approximately $3.26.
How much money does Anixa Biosciences make?: Anixa Biosciences (NASDAQ:ANIX) has a market capitalization of $101.29 million and generates $510,000.00 in revenue each year. The company earns $-13,600,000.00 in net income (profit) each year or ($0.35) on an earnings per share basis.
How can I contact Anixa Biosciences?: Anixa Biosciences' mailing address is 3150 ALMADEN EXPRESSWAY SUITE 250, SAN JOSE CA, 95118. The official website for the company is www.anixa.com. The company can be reached via phone at (408) 708-9808, via email at mcatelani@ituscorp.com, or via fax at 631-549-5974.

This page (NASDAQ:ANIX) was last updated on 9/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial